

Table S3: Prevalence categories with number of articles, estimated pooled prevalence, and I^2

Category	Number of Articles	Pooled Prevalence [95% CI]	I^2
Overall Analgesic ^{14, 16-18, 20, 23, 25, 29, 33, 36, 37, 43, 45, 46, 48, 49, 52}	17	50.8% [38.3-63.3%]	99.4%
Opioid ^{14-16, 18, 19, 21, 24, 26, 31, 37, 38, 40, 44}	13	23.8% [15.2-33.7%]	100.0%
Weak Opioid ^{17, 20, 23, 26, 36, 43, 45, 46}	8	17.1% [10.8-24.5%]	83.8%
Tramadol ^{16, 19, 33, 37, 38, 43, 48}	7	7.7% [2.2-16.0%]	99.9%
Codeine ^{20, 37, 38, 48}	4	5.7% [1.1-13.6%]	99.9%
Propoxyphene ^{16, 20, 38}	3	1.6% [0.9-2.4%]	60.6%
Strong Opioid ^{20, 26, 33, 36, 45, 46}	6	6.7% [3.2-11.2%]	74.8%
Oxycodone ^{16, 20, 37, 38, 48}	5	7.7% [1.4-18.4%]	99.9%
Morphine ^{20, 37, 38, 48}	4	1.2% [0.4-2.5%]	99.2%
Hydrocodone ^{16, 38, 48}	3	17.1% [1.7-43.7%]	100.0%
Hydromorphone ^{20, 38, 48}	3	2.3% [0.4-5.5%]	99.8%
Fentanyl ^{20, 38, 48}	3	2.0% [0.7-3.8%]	99.5%
Methadone ^{20, 37, 48}	3	0.9% [0.2-1.8%]	51.6%
Pethidine ²⁰	1	1.0% [0.0-4.1%]	N/A
NSAID ^{14, 15, 19, 20, 22, 26-28, 30, 32, 34, 35, 37, 39-42, 47, 50}	19	17.2% [12.6-22.3%]	99.6%
Diclofenac ^{22, 30, 33, 37, 39, 50}	6	3.0% [0.9-6.2%]	89.6%
Ibuprofen ^{22, 33, 37, 39, 50}	5	9.5% [3.6-17.7%]	95.8%
Cox-2 Inhibitors ^{30, 39, 50}	4	4.0% [1.1-8.4%]	84.6%
Ketoprofen ^{30, 33}	2	20.5% [1.1-53.8%]	96.6%
Naproxen ^{37, 39}	2	1.2% [1.0-1.5%]	0.0%
Nimesulide ³⁰	1	7.1% [3.0-12.8%]	N/A
Ketolorac ³⁰	1	7.1% [3.0-12.8%]	N/A
Dexketoprofen ⁵⁰	1	1.9% [0.2-4.8%]	N/A
Indomethacin ³⁷	1	1.0% [0.1-2.5%]	N/A
Acemetacin ²²	1	0.9% [0.0-4.0%]	N/A
Piroxicam ³⁰	1	0.9% [0.0-3.8%]	N/A
Etodolac ³⁷	1	0.3% [0.0-1.4%]	N/A
Salsalate ³⁷	1	0.3% [0.0-1.4%]	N/A
Other NSAID ^{30, 33, 39}	3	7.0% [3.1-12.1%]	80.5%
Acetaminophen ^{14, 15, 19, 20, 33, 36, 37, 43}	8	27.5% [17.6-38.5%]	98.6%
Adjuvants ^{19, 20, 26, 36, 43}	5	23.4% [16.5-31.0%]	58.4%
Non-Opioid ^{16-18, 20, 23, 37, 38, 46}	8	26.8% [19.2-35.2%]	96.9%
Tricyclic Antidepressants ⁵³	1	1.7% [1.7-1.8%]	N/A